肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)

中国临床肿瘤学会肿瘤与血栓专家委员会

中国临床肿瘤学会肿瘤与血栓专家委员会. 肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)[J]. 中国肿瘤临床, 2019, 46(13): 653-660. doi: 10.3969/j.issn.1000-8179.2019.13.765
引用本文: 中国临床肿瘤学会肿瘤与血栓专家委员会. 肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)[J]. 中国肿瘤临床, 2019, 46(13): 653-660. doi: 10.3969/j.issn.1000-8179.2019.13.765

肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)

doi: 10.3969/j.issn.1000-8179.2019.13.765
  • 图  1  DVT和浅静脉血栓的诊断流程

    图  2  PE的诊断流程

    图  3  DVT的治疗

    1)导管直接溶栓治疗的标准治疗方案包括尿激酶(12~18)万U/h,重组阿替普酶(rtPA)0.5~1.0 mg/h,重组瑞替普酶0.25~0.75 U/h或替奈普酶0.25~0.50 mg/h;2)DVT治疗疗程至少3~6个月

    图  4  PE的治疗

    1)阿替普酶(t-PA)50 mg或100 mg,静脉滴注2 h以上,是适合溶栓治疗的PE患者推荐溶栓疗法;2)PE治疗疗程至少6~12个月

    图  5  导管相关血栓的治疗

    图  6  预防VTE的流程图

    图  7  VTE预防流程图

    表  1  常用影像学检查方法(按优先顺序排列)

    表  2  常用实验室检测指标

    表  3  常用影像学检查方法(按优先顺序排列)

    表  4  常用实验室检测指标及其他

    表  5  PE严重指数简化版(sPESI)

    表  6  抗凝治疗预防方法和适应证

    表  7  多发性骨髓瘤患者的VTE预防

    表  8  VTE的Khorana风险评估模型(2014年)

    附录  常见抗凝药物及逆转药物的使用

  • [1] Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor[J]. Hamostaseol, 2012, 32(2):95-104. doi: 10.5482/ha-1160
    [2] Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism:the seventh ACCP conference on antithrombotic and thrombolytic therapy[J]. Chest, 2004, 126(3 Suppl):338s-400s. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_JJ021049344
    [3] Khorana AA. Venous thromboembolism prevention in cancer outpatients[J]. J NCCN, 2013, 11(11):1431-1438. http://d.old.wanfangdata.com.cn/Conference/8528926
    [4] 中国临床肿瘤学会(CSCO)肿瘤与血栓专家共识委员会.肿瘤相关静脉血栓栓塞症预防与治疗中国专家指南(2015版)[J].中国肿瘤临床, 2015, 42(20):979-991. doi: 10.3969/j.issn.1000-8179.2015.20.015
    [5] Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer[J]. N Engl J Med, 2002, 346(13):975-980. doi: 10.1056/NEJMoa012385
    [6] Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters:final results of a double-blind, placebo-controlled phase Ⅲ trial[J]. Ann Oncol, 2006, 17(2):289-296. doi: 10.1093/annonc/mdj059
    [7] Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The catheter study)[J]. J Thrombosis and Haemostasis, 2007, 5(8):1650-1653. doi: 10.1111/j.1538-7836.2007.02613.x
    [8] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease:Antithrombotic therapy and prevention of thrombosis, 9th ed:American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e419S-e496S.
    [9] Jaff MR, Mcmurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension:a scientific statement from the American heart association[J]. Circulation, 2011, 123(16):1788-1830. doi: 10.1161/CIR.0b013e318214914f
    [10] Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer[J]. Archi Int Med, 2004, 164(15):1653-1661. doi: 10.1001/archinte.164.15.1653
    [11] Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du risque d'Embolie pulmonaire par interruption cave study group[J]. N Engl J Med, 1998, 338(7):409-415. doi: 10.1056/NEJM199802123380701
    [12] Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists:the seventh ACCP conference on antithrombotic and thrombolytic therapy[J]. Chest, 2004, 126(3 Suppl):204s-233s. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0272989X05279253
    [13] NCCN guidelines. Cancer-associated venous thromboembolic disease version 2.2018-August 27, 2018 www.nccn.org.
    [14] Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral gactor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:results of a randomized trial (SELECTD)[J]. J Clin Oncol, 2018, 36(20):2017-2023. doi: 10.1200/JCO.2018.78.8034
    [15] Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism:guidance from the SSC of the ISTH[J]. J Thrombosis and Haemostasis, 2018, 16(9):1891-1894. doi: 10.1111/jth.14219
    [16] Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer:ASCO clinical practice guideline update[J]. J Clin Oncol, 2019, 37:1-27.DOI: 10.1200/JCO.19.01461
    [17] Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer[J]. N Engl J Med, 2019, 380(8):720-728. doi: 10.1056/NEJMoa1814630
    [18] Wang ZF, Zwicker JI, Cihan AY, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients:Guidance from the SSC of the ISTH[J]. J Thrombosis and Haemostasis, 2019, 17(7):1-7. DOI: 10.1111/jth.14564
  • 加载中
图(7) / 表(9)
计量
  • 文章访问数:  776
  • HTML全文浏览量:  121
  • PDF下载量:  393
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-06-30
  • 刊出日期:  2019-07-15

目录

    /

    返回文章
    返回